{"id":33607,"date":"2020-08-14T11:50:39","date_gmt":"2020-08-14T10:50:39","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33607"},"modified":"2021-03-19T09:48:47","modified_gmt":"2021-03-19T09:48:47","slug":"inhalation-respiratory-drug-delivery-2019-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/","title":{"rendered":"Inhalation & Respiratory Drug Delivery 2019 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33724″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/badre-hammond\/badre_hammond_aptar_pharma_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Badre_Hammond_Aptar_Pharma_BioTech_Pharma_Summit_1-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tBadre Hammond\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Corporate Business Integration at Aptar Pharma<\/h5>\n

\n\t\t\t\n\tIntroducing novel platform technology of three phase polymer technology integrated into inhaler packaging to protect drug product from oxygen, moisture, and VOCs\n\t\t\t<\/a>\n\t<\/h3>\n\t

Badre Hammond\u2019s background is in Biochemistry and drug development with 15 years\u2019 experience in pharmaceutical product development with focus on nasal and pulmonary drug delivery systems. Mr. Hammond has broad experience in managing development of novel drug product programs from formulation development, pre-clinical, CMC, to market launch.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33716″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/boris-shekunov\/boris_shekunov_takeda_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.4","credit":"","camera":"iPhone 4S","caption":"","created_timestamp":"1411571159","copyright":"","focal_length":"1.85","iso":"125","shutter_speed":"0.0013192612137203","title":"","orientation":"1"}” data-image-title=”Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Boris_Shekunov_Takeda_BioTech_Pharma_Summit_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tBoris Shekunov\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director \/ Sr. Principal Scientist at Takeda Pharmaceutical Company<\/h5>\n

\n\t\t\t\n\tModeling and Characterization of Powder Dispersion in DPIs\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr Boris Shekunov\u2019s major scientific interests lie in the areas of particle technology, solid-state chemistry, pharmaceutics of drug delivery and pharmaceutical analysis. His career started in the UK academia.<\/p>\n

Since 2002, he directed different research groups in the US pharmaceutical industry. At Takeda, he oversees analytical and materials science aspects of the late development and commercial products. He is an author of over 100 publications and 30 patents.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33710″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/donovan-yeates\/donovan_yeates_kaer_biotherapeutics_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"Canon EOS 60D","caption":"","created_timestamp":"1361107422","copyright":"","focal_length":"50","iso":"640","shutter_speed":"0.8","title":"","orientation":"1"}” data-image-title=”Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Donovan_Yeates_Kaer_Biotherapeutics_BioTech_Pharma_summit_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDonovan B. Yeates\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Donovan B. Yeates CEO at KAER Biotherapeutics Corporation<\/h5>\n

\n\t\t\t\n\tDelivery of Therapeutic Aerosols to Critically Ill Patients\n\t\t\t<\/a>\n\t<\/h3>\n\t

Donovan B. Yeates, Ph.D., CEO, KAER Biotherapeutics Corporation, is an internationally recognized authority in aerosol drug delivery and respiratory function. Has developed technologies to deliver aerosols to the lungs, quantify the dose delivered and evaluate the physiological mechanisms whereby they are cleared from the lungs.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33704″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/dries-cardoen\/dries_cardoen_nelson_labs_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"FILIP CLAESSENS","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dries_Cardoen_Nelson_Labs_BioTech_Pharma_Summit_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDries Cardoen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Sr. Study Director at Nelson Labs<\/h5>\n

\n\t\t\t\n\tExtractables and leachables: what\u2019s in a name?\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dries Cardoen received his Ph.D. from the Faculty of Biology at the University of Leuven (Belgium) in 2011. After his academic career as a post-doctoral researcher, he started at Nelson Labs (formerly Toxikon Europe) in 2013 as study director in the Extractables & Leachables Department. He is currently leading the team of study directors that is specialized in E&L testing of inhalation drug products and topical and transdermal drug products.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33740″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/guenther-hochhaus\/guenther_hochhaus_university_florida_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Guenther_Hochhaus_University_Florida_BioTech_Pharma_Summit_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tGuenther Hochhaus\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor at University of Florida<\/h5>\n

\n\t\t\t\n\tInhalation therapy for pulmonary arterial hypertension, a pulmonary vascular disease\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Guenther Hochhaus received his Ph.D. in 1984 at the Institute of Pharmaceutical Chemistry, Westf. Wilhems University (M\u00fcnster, Germany). He completed a postdoctoral fellowship at the University of California-San Francisco and subsequently joined the University of Florida\u2019s College of Pharmacy.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”24030″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/jan-de-backer\/jan_de_backer_fluidda_biotech_pharma_summit_inhalation_drug_delivery_respiratory_profile_gallery\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Jan_De_Backer_Fluidda_BioTech_Pharma_Summit_Inhalation_Drug_delivery_Respiratory_Profile_Gallery-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJan De Backer\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at FLUIDDA<\/h5>\n

\n\t\t\t\n\tBringing better inhaled drugs faster to market through Functional Respiratory Imaging and Artificial Intelligence\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Jan De Backer graduated from Delft University of Technology, The Netherlands as aerospace engineer. He attained an MSc degree in aerodynamics and specialised in applied biomedical computational fluid dynamics leading to a PhD from the University of Antwerp, Belgium. He is an alumnus of the MBA programs at London Business School, London and Columbia Business School, New York.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33693″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/john-patton\/john_patton_dance_biopharm_biotech_pharma_summit_1-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Patton_Dance_Biopharm_BioTech_Pharma_Summit_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJohn Patton\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chairman & CSO at Dance Biopharm<\/h5>\n

\n\t\t\t\n\tInhaled insulin: More compelling than ever!\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. John Patton began Dance Biopharm operations in 2010 with a carefully selected core team. Previously, he was the co-founder of Inhale Therapeutics (now Nektar Therapeutics), where he helped lead the development and FDA approval of the first inhaled insulin product. During his 18-year tenure at Inhale, Patton was a key driver for the company\u2019s business development deals and participated in financings totaling more than $700M.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”24043″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/justin-kalafat\/justin_kalafat_acg_biotech_pharma_summit_inhalation_drug_delivery_acg_respiratory_capsules_irdd\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.8","credit":"","camera":"NIKON D750","caption":"","created_timestamp":"1546866929","copyright":"","focal_length":"62","iso":"160","shutter_speed":"0.003125","title":"","orientation":"1"}” data-image-title=”Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Justin_Kalafat_ACG_BioTech_Pharma_Summit_Inhalation_Drug_delivery_ACG_Respiratory_capsules_IRDD-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJustin Kalafat\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Scientific Business Development Manager at ACG<\/h5>\n

\n\t\t\t\n\tOpportunities, Trends & Possibilities with Capsule Based Inhalation Technology\n\t\t\t<\/a>\n\t<\/h3>\n\t

Justin Kalafat is responsible for collaborating with pharmaceutical industry for capsule business. Prior to joining ACG in 2014, his background includes degrees in chemistry and roles within the generic pharmaceutical industry in quality control and procurement.<\/p>\n

His experiences enable key strategies to be developed with customers, R&D focused institutions and universities on the technical aspects of capsules as a dosage form solution.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33687″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/kristen-merriman\/kristen_merriman_sanford_biotech_pharma_summit_1-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Kristen_Merriman_Sanford_BioTech_Pharma_Summit_1-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tKristen Merriman\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director of Respiratory Care Services, Pulmonary Function Laboratory & Interventional Pulmonary Program at Stanford University Medical Center<\/h5>\n

\n\t\t\t\n\tChallenges and Limitations with Continuous Administration of Inhaled Prostacyclins\n\t\t\t<\/a>\n\t<\/h3>\n\t

Kristen Merriman has worked in respiratory therapy for over 25-years specializing in adult and pediatric emergency and critical care. While providing for patients at the bedside, she completed her advanced degrees in astrophysics and spent two years analyzing the chemical composition of star clusters around fossil galaxies to understand their evolutionary history. She has served as an instructor of both respiratory care and physics at the undergraduate level.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33746″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/larry-brown\/larry_brown_noveome_biotherapeutics_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Larry_Brown_Noveome_Biotherapeutics_BioTech_Pharma_Summit_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tLarry Brown\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Executive Vice President of R&D and Chief Scientific Officer at Noveome Biotherapeutics<\/h5>\n

\n\t\t\t\n\tTargeted intranasal nose-to-brain delivery of a novel amnion cell-derived biotherapeutic product\n\t\t\t<\/a>\n\t<\/h3>\n\t

Larry Brown, Sc.D., serves as the Executive Vice President of R&D and Chief Scientific Officer of Noveome Biotherapeutics.<\/p>\n

He obtained his doctorate in Biochemistry and Bioengineering at the Massachusetts Institute of Technology under Prof. Robert Langer and trained in the late Dr. Judah Folkman\u2019s laboratory in the Surgical Research Department of Childrens Hospital, Boston.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”24058″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/masahiro-sakagami\/masahiro_sakagami_virginia_university_biotech_pharma_summit_inhalation_respiratory_drug_delivery_gallery\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Masahiro_Sakagami_Virginia_University_BioTech_Pharma_Summit_Inhalation_Respiratory_Drug_Delivery_gallery-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMasahiro Sakagami\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor of Pharmaceutics at Virginia Commonwealth University School of Pharmacy<\/h5>\n

\n\t\t\t\n\tNovel caffeic acid-based oligomer molecules for pulmonary delivery: reversal of emphysema\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Masahiro Sakagami is a Professor in the Department of Pharmaceutics at the Virginia Commonwealth University (VCU) School of Pharmacy in Richmond, Virginia, USA. He received B.S. and M.S. in Chemical Engineering at Waseda University in Japan (1989 and 1991, respectively); and a Ph.D. in Pharmaceutical Sciences at VCU (2000). In 1991-1996, he was an inhalation drug delivery scientist at Teijin Ltd., a pharmaceutical industry in Japan.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33674″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/nicolas-buchmann\/nicolas_buchmann_biotech_pharma_summit_vectura_group_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nicolas_Buchmann_BioTech_Pharma_Summit_Vectura_Group_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tNicolas Buchmann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Programme Manager at Vectura Group plc.<\/h5>\n

\n\t\t\t\n\tSmart Nebulisers – Opportunities for Development of Drug Products\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Nicolas Buchmann is Programme Manager at Vectura Group plc. He has gained extensive experience as Programme and Project Manager and is leading drug-device combination programmes with pMDIs, development projects with connected inhalation devices, smart nebuliser technology developments and was also deeply involved in the development of novel aerosol generation technologies. At his work at Vectura. His educational background is engineering profession with a Doctor of Philosophy in Mechanical and Biomedical Engineering<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33731″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/roy-barnewall\/roy_barnewall_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"DSC-P92","caption":"","created_timestamp":"1073654489","copyright":"","focal_length":"8","iso":"100","shutter_speed":"0.002","title":"","orientation":"1"}” data-image-title=”Roy_Barnewall_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roy_Barnewall_BioTech_Pharma_Summit_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRoy Barnewall\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Manager: Inhalation Technology at Battelle<\/h5>\n

\n\t\t\t\n\tRegulatory and Logistical Challenges and Complexities in Testing Products for Safety and Efficacy Against Highly Infectious Inhaled Microorganism\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Roy Barnewall has 25 years of experience in veterinary medicine and biomedical research experience in Inhalation, bacterial pathogenesis, medical countermeasures, and animal model development. Dr Barnewall has been at Battelle for 19+ years, where he serves as Research Leader and Manager of the Inhalation department, as well as a veterinarian, a scientist, and study director.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33680″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/samir-shah\/samir_shah_teva_biotech_pharma_summit_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Samir_Shah_Teva_BioTech_Pharma_Summit_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Samir_Shah_Teva_BioTech_Pharma_Summit_1-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSamir Shah\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Associate Director, Regulatory Affairs, Combination Products at Teva Pharm<\/h5>\n

\n\t\t\t\n\tRegulatory Success with a Digital Combination Product\n\t\t\t<\/a>\n\t<\/h3>\n\t

Peter Robbins is Professor of Physiology at the University of Oxford. He has a strong reputation for developing innovative technologies to address previously intractable questions in human physiology, particularly relating to respiratory and cardiovascular function. His interests include hypoxia biology and iron homeostasis. In these areas, he has had a long-term collaboration with Professor Sir Peter Ratcliffe, the 2019 Nobel Laureate in Physiology or Medicine.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”24092″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/wayland-rushing\/wayland_rushing_eurofins_biotech_pharma_summit_irdd_inhalation_respiratory_drug_delivery_new_york\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5","credit":"","camera":"NIKON D5500","caption":"","created_timestamp":"1531857089","copyright":"","focal_length":"40","iso":"800","shutter_speed":"0.01","title":"","orientation":"1"}” data-image-title=”Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Wayland_Rushing_Eurofins_BioTech_Pharma_Summit_IRDD_Inhalation_Respiratory_Drug_Delivery_New_York-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tWayland Rushing\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Scientific Affairs at Eurofins BioPharma Product Testing<\/h5>\n

\n\t\t\t\n\tAnalytical Challenges in Implementing Effective QC\/Stability Testing of Inhalation Drug Products\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Wayland Rushing has 20 years of CMC analytical testing experience, including over 15 years of experience in testing of inhalation drug products.<\/p>\n

As the Director of Scientific Affairs he is responsible for designing and implementing CMC testing programs for Eurofins clients, including programs for pMDI\u2019s, DPI\u2019s, Nebulizers, pre-filled syringes along with a variety of other drug delivery and container\/closure systems.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33698″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/yvonne-chan\/yvonne_chan_mount_sinai_inhalation_respiratory_drug_delivery_2019_new_york_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1484690581","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yvonne_Chan_Mount_Sinai_Inhalation_Respiratory_drug_delivery_2019_New_york_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tYvonne Chan\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Center for Digital Health at Icahn School of Medicine at Mount Sinai<\/h5>\n

\n\t\t\t10,000 participants from 3 countries.” target=”_self” rel=”noopener noreferrer”>\n\tThe Mount Sinai Asthma Mobile Health Study powered by Apple\u2019s ResearchKit framework is a remote observation study that enrolled >10,000 participants from 3 countries.\n\t\t\t<\/a>\n\t<\/h3>\n\t

Yvonne Yu-Feng Chan, MD, PhD, is Director of the Digital Health Center at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. She is a national leader in mobile health and digital health research, and a board-certified Emergency physician.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Boris Shekunov Director \/ Sr. Principal Scientist at Takeda Pharmaceutical Company Modeling and Characterization of Powder Dispersion in DPIs Dr Boris Shekunov\u2019s major scientific interests lie in the areas of particle technology, solid-state chemistry, pharmaceutics of drug delivery and pharmaceutical analysis. His career started in the UK academia. Since 2002, he directed…<\/p>\n","protected":false},"author":1,"featured_media":33608,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33607","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nInhalation & Respiratory Drug Delivery 2019 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"On 30 & 31 May 2019, New York (USA) hosted the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 (IRDD) conference at the Crowne Plaza Times Square.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhalation & Respiratory Drug Delivery 2019 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"On 30 & 31 May 2019, New York (USA) hosted the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 (IRDD) conference at the Crowne Plaza Times Square.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-19T09:48:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"993\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/\",\"name\":\"Inhalation & Respiratory Drug Delivery 2019 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png\",\"datePublished\":\"2020-08-14T10:50:39+00:00\",\"dateModified\":\"2021-03-19T09:48:47+00:00\",\"description\":\"On 30 & 31 May 2019, New York (USA) hosted the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 (IRDD) conference at the Crowne Plaza Times Square.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png\",\"width\":1920,\"height\":993},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhalation & Respiratory Drug Delivery 2019 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhalation & Respiratory Drug Delivery 2019 Speakers • BioTech Pharma Summit","description":"On 30 & 31 May 2019, New York (USA) hosted the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 (IRDD) conference at the Crowne Plaza Times Square.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Inhalation & Respiratory Drug Delivery 2019 Speakers • BioTech Pharma Summit","og_description":"On 30 & 31 May 2019, New York (USA) hosted the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 (IRDD) conference at the Crowne Plaza Times Square.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-19T09:48:47+00:00","og_image":[{"width":1920,"height":993,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/","name":"Inhalation & Respiratory Drug Delivery 2019 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png","datePublished":"2020-08-14T10:50:39+00:00","dateModified":"2021-03-19T09:48:47+00:00","description":"On 30 & 31 May 2019, New York (USA) hosted the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 (IRDD) conference at the Crowne Plaza Times Square.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/IRDD_Inhalation_Respiratory_Drug_Delivery_New_York_2019.png","width":1920,"height":993},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/inhalation-respiratory-drug-delivery-2019-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Inhalation & Respiratory Drug Delivery 2019 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33607"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33607\/revisions"}],"predecessor-version":[{"id":36160,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33607\/revisions\/36160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33608"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}